Methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in metastatic breast cancer patients

L. Merlini, V. Secondo, S. Mammoliti, P. Bellotti, C. Castello, L. Gallo

Research output: Contribution to journalArticle

Abstract

We have evaluated the efficacy and toxicity of a chemotherapy consisting of methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in 21 advanced breast cancer patients. Among 20 evaluable patients, objective response was obtained in 6 patients (30%) with two complete responses, stable disease in 4 patients (20%), while 10 patients (50%) progressed. Median progression-free survival and survival were 10 and 15 months, respectively. The most frequently observed side-effects were myelosuppression and emesis; one patient, who had previously received doxorubicin at the maximum dose-limiting cardiac toxicity, died of congestive heart failure after the third cycle. This treatment is moderately effective for advanced breast cancer patients.

Original languageEnglish
Pages (from-to)1423-1425
Number of pages3
JournalAnticancer Research
Volume14
Issue number3 B
Publication statusPublished - 1994

Keywords

  • Biochemical modulation
  • Breast cancer
  • Salvage treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in metastatic breast cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Merlini, L., Secondo, V., Mammoliti, S., Bellotti, P., Castello, C., & Gallo, L. (1994). Methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in metastatic breast cancer patients. Anticancer Research, 14(3 B), 1423-1425.